Adagrasib(Krazati) is a targeted drug for the treatment of KRAS G12C mutation-positive non-small cell lung lesions (NSCLC). It blocks the growth and spread of diseased cells by inhibiting the activity of KRAS G12C mutant protein, helping patients prolong survival and improve their quality of life. Adagrasib's indications are mainly concentrated in specific groups of patients with gene mutations.
What are the specific indications of Adagrasib(Krazati)?
Adagrasib is suitable for adult patients with locally advanced or metastatic non-small cell lung lesions (NSCLC) who have been confirmed as KRAS G12C mutations by FDA-approved testing and have received at least one systemic treatment. It helps patients control the growth and spread of lesions by inhibiting the activity of KRAS G12C mutant protein.
Non-small cell lung lesions with KRAS G12C mutation Adagrasib is mainly used to treat patients with KRAS G12C mutation-positive non-small cell lung lesions. KRAS G12C mutation is one of the common driver mutations in NSCLC. Adagrasib helps patients control the growth and spread of lesions by selectively inhibiting this mutant protein.
Locally advanced or metastatic NSCLC
Adagrasib is suitable for patients with locally advanced or metastatic non-small cell lung lesions, especially those who have received one systemic treatment but their condition still progresses. It helps patients prolong survival and improve their quality of life by inhibiting the activity of KRAS G12C mutant protein.
The indications of Adagrasib are mainly concentrated in patients with KRAS G12C mutation-positive non-small cell lung lesions. Next, we will introduce the contraindications of Adagrasib.
Contraindications of Adagrasib
The use of Adagrasib requires special attention, and certain specific populations should avoid using the drug. Especially for patients with congenital long QT syndrome and patients with severe liver damage, Adagrasib needs to be used with extreme caution.
Patients with congenital long QT syndrome
Adagrasib may cause QT interval prolongation and increase the risk of ventricular arrhythmias, especially ventricular fibrillation. Patients with congenital long QT syndrome should avoid the use of Adagrasib to reduce the risk of arrhythmias.
Patients with severe liver damage
Adagrasib may cause hepatotoxicity, and patients with severe liver damage should avoid using the drug. Before using Adagrasib, patients should undergo liver function tests and monitor liver function regularly during medication.
The use of Adagrasib needs to be adjusted according to the specific situation of the patient, especially for people with contraindications. Next, we will introduce the laboratory abnormalities of Adagrasib.
What tests can be done for laboratory abnormalities of Adagrasib?
The use of Adagrasib may cause some laboratory abnormalities, and patients should undergo relevant tests regularly during medication.
Liver function test
Adagrasib may cause hepatotoxicity. Patients should undergo regular liver function tests during medication, including indicators such as alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase and total bilirubin. If liver function abnormalities occur, the doctor may adjust the dose or suspend the medication.
Electrocardiogram and electrolyte tests
Adagrasib may cause QT interval prolongation. Patients should undergo regular electrocardiogram and electrolyte tests during medication, especially potassium, magnesium and other electrolyte levels. If QT interval prolongation or electrolyte abnormalities occur, the doctor may adjust the dose or suspend the medication.
The use of Adagrasib requires regular laboratory tests. Patients should strictly follow the doctor's instructions during medication, and have regular reexaminations to prevent possible serious adverse reactions.
